PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study

Erland Erdmann¹, John Dormandy², Robert Wilcox³, Massimo Massi-Benedetti⁴, Bernard Charbonnel⁵

¹University of Cologne, Cologne, Germany; ²Department of Clinical Vascular Research, St Georges Hospital, London, UK; ³Department of Cardiovascular Medicine, Queen’s Medical Centre, University Hospital, Nottingham, UK; ⁴University of Perugia, Medicine and Metabolic Diseases, Perugia, Italy; ⁵Clinique d’Endocrinologie, Hôtel Dieu, Nantes Cedex 1, France

Abstract: Patients with type 2 diabetes face an increased risk of macrovascular disease compared to those without. Significant reductions in the risk of major cardiovascular events can be achieved with appropriate drug therapy, although patients with type 2 diabetes remain at increased risk compared with non-diabetics. The thiazolidinedione, pioglitazone, is known to offer multiple, potentially antiatherogenic, effects that may have a beneficial impact on macrovascular outcomes, including long-term improvements in insulin resistance (associated with an increased rate of atherosclerosis) and improvement in the atherogenic lipid triad (low HDL-cholesterol, raised triglycerides, and a preponderance of small, dense LDL particles) that is observed in patients with type 2 diabetes. The recent PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study showed that pioglitazone can reduce the risk of secondary macrovascular events in a high-risk patient population with type 2 diabetes and established macrovascular disease. Here, we summarize the key results from the PROactive study and place them in context with other recent outcome trials in type 2 diabetes.

Keywords: pioglitazone, macrovascular disease, type 2 diabetes, secondary prevention